SeaCrest Wealth Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

SeaCrest Wealth Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-510	Closed	-$3K	–	1967
2019 Q1	$3K	Hold	510	–	–	﹤0.01%	1877
2018 Q4	$2K	Buy	510 +10	+2%	+$55	﹤0.01%	1945
2018 Q3	$4K	Hold	500	–	–	﹤0.01%	1941
2018 Q2	$5K	Hold	500	–	–	﹤0.01%	1833
2018 Q1	$4K	Sell	500 -300	-38%	-$3.23K	﹤0.01%	1859
2017 Q4	$10K	Buy	+800	New	+$9.17K	﹤0.01%	1612

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SeaCrest Wealth Management's ZYNE Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2019, closing a stake of 510 shares — an estimated $3K sold.

SeaCrest Wealth Management first reported a position in ZYNE in Q4 2017 and held it in 6 quarters. The position peaked at $10K in Q4 2017. 76 funds tracked by Wall St. Rank hold ZYNE as of Q2 2019.

SeaCrest Wealth Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 510 Zynerba Pharmaceuticals, Inc shares in Q2 2019, an estimated $3K.
SeaCrest Wealth Management first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Zynerba Pharmaceuticals, Inc position peaked at $10K in Q4 2017.
76 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.